A Study to Assess the Effectiveness and Safety of Pacritinib in Patients With VEXAS Syndrome (PAXIS)
brief summary
This trial is to assess the effectiveness and safety of pacritinib in patients with VEXAS (i.e., Vacuoles in myeloid progenitors, E1 ubiquitin-activating enzyme, X-linked, autoinflammatory manifestations, and somatic) syndrome. In phase 2a, approximately 78 participants will be randomized to either pacritinib dose A, pacritinib dose B + placebo, or placebo. In Phase 2b, approximately 78 participants will be randomized. Phase 2b participants will initially be randomized to either pacritinib dose A, pacritinib dose B + placebo, or placebo. After dose selection, Phase 2b further participants will be randomized to either the selected pacritinib dose or placebo. Randomization will be stratified by prescribed GC dose on the day of randomization.
detailed description
This trial is a randomized, multicenter, double-blind, placebo-controlled phase 2a and 2b trial designed to evaluate the efficacy and safety of pacritinib for the prevention of VEXAS flares after glucocorticoid (GC) taper. The trial will enroll participants ≥18 years with inflammatory VEXAS syndrome receiving ongoing GC therapy for ≥4 consecutive weeks, requiring between 15 and 45 mg daily (of prednisone / prednisolone or equivalent) at the time of enrollment (randomization).
In phase 2a, participants will be randomized 1:1:1 to receive pacritinib dose A (n=26), pacritinib dose B plus placebo (n=26), or placebo (n=26) for up to 24 weeks during a double-blind treatment period, followed by treatment with pacritinib during an open-label treatment period for up to 48 weeks.
In Phase 2b, approximately 78 participants will be randomized (enrollment starts after completion of Phase 2a enrollment). Randomization will initially be conducted in a 1:1:1 ratio to receive pacritinib dose A, pacritinib dose B plus placebo, or placebo, consistent with Phase 2a. Following Phase 2a results, a single pacritinib dose will be selected for continued evaluation. After dose selection, Phase 2b further participants will be randomized in a 2:1 ratio of the selected pacritinib dose to placebo until the total target of 78 participants are randomized.
Randomization will be stratified by prescribed GC dose on the day of randomization. All outcomes will be reported by treatment arm, and comparisons between each pacritinib arm and placebo (Phase 2a) or between the selected pacritinib dose and placebo (Phase 2b) will be performed in the double-blind treatment periods.
Participants who complete the double-blind treatment period at EOW 24 or meet Early Failure criteria at EOW 12 will transition to an open-label pacritinib treatment period through EOW 48. In addition, if a trial arm closes (due to interim futility or safety in Phase 2a or due to dose selection in Phase 2b), all participants currently randomized to the terminated arm will transition to open-label treatment.
Participants who complete the open-label treatment period at End of Week (EOW) 48 and who are benefitting from pacritinib in the opinion of the Investigator may continue to receive treatment for an additional 2 years on the extension period. Participants who discontinue study treatment will have a 30-day post-End of Treatment (EOT) follow-up period.
The trial (including the double-blind and open-label treatment periods, as well as the extension period) is planned to end approximately 3 years from the first dose of the last participant.
official title
PAXIS: A Phase 2a and 2b Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Pacritinib in Patients With VEXAS Syndrome